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CONCISE REPORTS
A genetic association study of the IGF-1 gene and
radiological osteoarthritis in a population-based
cohort study (the Rotterdam study)
I Meulenbelt, C Bijkerk, H S Miedema, F C Breedveld, A Hofman, H A Valkenburg,
H A P Pols, P E Slagboom, C M van Duijn
Abstract
Objective—A genetic association study
was performed to investigate whether
radiographical osteoarthritis (ROA) was
associated with specific genotypes of the
insulin-like growth factor I (IGF-1) gene.
Methods—Subjects aged 55–65 years were
selected from a population-based study of
which ROA at the knee, hip, spine, and
hand was assessed. Genotypes were deter-
mined of a polymorphism in the promoter
region of the IGF-1 gene.
Results—The IGF-1 locus was significantly
associated with the presence of ROA (over-
all adjusted OR for heterozygous subjects =
1.9, 95% CI 1.2, 3.1 and for homozygous
subjects 3.6, 95% CI 0.8, 16.2).
Conclusion—These results suggest that
variation at the IGF-1 locus is associated
with ROA development and may play a
part in ROA pathogenesis. To confirm
these findings replication in another
population-based sample is needed.
(Ann Rheum Dis 1998;57:371–374)
Osteoarthritis (OA) is a disease characterised
by the degradation of articular cartilage and
formation of new bone (osteophytes and
sclerosis). Several reports suggest that genetic
influences contribute considerably to the de-
velopment of OA.1 2 The relevance of the
genetic component, however, varies among
subgroups of patients and as yet it is not clear
which genes are involved.3
Insulin-like growth factor 1 (IGF-1) stimu-
lates chondrocytes to synthesise extracellular
matrix (ECM) components in cartilage.4 5 Its
action is mediated through the type 1 IGF
receptor. The function of IGF-1 and its receptor
in cartilage formation both during developmen-
tal stages and remodelling of adult cartilage may
be relevant to the aetiology of OA. IGF-1 may
also influence OA by osteophyte formation.6
Although osteophyte growth during OA pro-
gression and bone mineral density (BMD) is
positively correlated to high serum IGF-1
concentrations,6 7 no consistent relation between
serum IGF-1 concentrations and OA has been
found.8 9 Furthermore, serum IGF-1 is inversely
correlated to age10 and body mass index
(BMI).11 As individual IGF-1 concentrations are
liable to temporal variations, assessing the role of
IGF-1 in OA by serum concentrations is
complex. We have examined the relation be-
tween the IGF-1 gene and the presence of
radiographical OA (ROA) in subjects aged
55–65 years.
Methods
SUBJECTS
Subjects were derived from a prospective
population-based cohort study of determinants
and prognosis of chronic diseases in the elderly,
the Rotterdam study.12 Weight bearing
anterior-posterior radiographs of the hips and
knees, anterior-posterior radiographs of the
hands and wrists, and lateral radiographs of the
spine (Th4-S1) were obtained from a random
cohort of 1040 unrelated people aged 55–65
years (425 men and 615 women). ROA was
assessed by two independent readers and by
means of the grading system proposed by
Kellgren.13 By applying these criteria a hip joint
with Kellgren score 2 requires the presence of
both definite joint space narrowing and definite
osteophytes. A knee or hand joint with
Kellgren score 2 requires the presence of defi-
nite osteophytes and possible narrowing of
joint space. A spine joint with Kellgren score 2
denotes definite lateral osteophytes. For both
knees and hips radiographs had previously
been scored.14 ROA of the hand was assessed in
each inter- and metacarpalphalangeal joint
individually, and the first carpometacarpal and
trapezoscaphoideal joint. ROA of the wrist was
assessed at the radiocarpal and distal radio-
ulnar joints. For the spine three levels, from
Th4 to S1, were scored with regard to
osteophytes and disc space narrowing, for
example, thoracic, lumbar and lumbosacral. In
the analysis definite ROA was defined as Kell-
gren score 2 or over in the left and/or right cor-
responding joint. Hand ROA was defined as
Kellgren score 2 or over in at least one of the 36
joints that were scored. For this purpose the
joints of the wrist were included in the category
hand ROA. ROA of the spine was defined as
Kellgren score 2 or over in at least one out of
three levels scored. The presence or absence of
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osteophytes of the knee were scored separately.
Information on age (in years), BMI (measured
as weight in kg divided by height2 in metres),
and BMD (measured as gram mineral divided
by area in cm2) of the neck of the femur were
used in the study. In view of the hypothesis that
the genetic contribution to ROA diVers in men
and women and may depend on the joint site,
stratified analysis was performed with respect
to sex and joint site.
GENOTYPING AND STATISTICAL ANALYSIS
Genotypes of the dinucleotide repeat polymor-
phism of the IGF-1 gene were determined as
previously described15 of 786 people for whom
cells were available. Patient characteristics (sex,
age, BMI, and BMD) were compared between
subjects with and without ROA by using t tests
for independent samples. Allele frequencies
were assessed by counting alleles and calculat-
ing sample proportions. The ÷2 test for Hardy
Weinberg equilibrium (HWE) was calculated
using the HWE-program (LINKUTIL
package).16 Alleles with an allele frequency <
0.05 were pooled. A likelihood ratio test was
used to test for association of IGF-1 alleles with
the occurrence of ROA.17 This method is
specifically suitable to perform association
studies with polymorphic markers with multi-
ple alleles. To measure the strength of associa-
tion between ROA and IGF-1 genotypes, a
logistic regression model was used to estimate
the odds ratio (OR). ORs were adjusted for risk
factors of OA—that is, sex, age, BMI and
BMD.ORs are presented with 95% confidence
intervals (95% CI). The statistical package
SPSS was used and p values < 0.05 (two sided)
were considered significant.
Results
Table 1 shows the number of genotyped people
with ROA (ROA+) and without ROA (ROA−)
in any of the joint sites investigated and the
mean age, BMI, and BMD. The mean age and
BMI diVered significantly between subjects
with and without ROA (p < 0.001). Only 17%
were free of ROA in every joint investigated in
this relatively young age group.
In total nine diVerent alleles were identified
(A1–A9) with allele frequencies ranging from
0.002–0.66. IGF-1 allele frequencies of the
four most frequent alleles are shown in table 1
for the random cohort, for ROA+ and for
ROA− subjects. Except for the relatively rare
allele A2, the IGF-1 allele frequencies observed
in the cohort, and the subjects with and
without ROA were similar as described by
Weber and May15 (see table 1). The low
frequency alleles A1 (frequency 0.02), A6 (fre-
quency 0.02), A7 (frequency 0.003), and A9
(frequency 0.002) (not shown in table 1) were
not previously described in a population-based
study.15 The distribution of genotype frequen-
cies was not significantly diVerent from that
expected for a population in HWE neither
overall (p = 0.76) nor for the ROA+ (p = 0.78)
or the ROA− group (p = 0.47).
Table 1 shows association of the IGF-1
polymorphism in ROA+ as compared with
ROA− subjects (p = 0.02). This association
was caused by diVerences in allele frequency
A3 and A4 between ROA+ and ROA−
subjects. The strength of the association of the
IGF-1 locus with ROA was estimated using a
logistic regression model (table 2). The overall
adjusted OR (age, sex, BMI, and BMD) for
ROA+ subjects heterozygous for IGF-1 allele
A3 was 1.9, 95% CI 1.2, 3.1. For subjects
homozygous for IGF-1 allele A3 (A3/A3) the
overall adjusted OR (age, sex, BMI, and
BMD) was 3.6, 95% CI 0.8, 16.2. A protective
eVect was observed for the IGF-1 allele A4
with an overall adjusted OR (age, sex, BMI,
and BMD) for heterozygous ROA+ subjects of
0.7, 95% CI 0.4, 1.5 and an overall adjusted
OR of 0.5, 95% CI 0.3, 1.0 for homozygous
A4/A4 subjects. Interaction in these analyses
with sex, age, BMI, and BMD was not
observed.
As IGF-1 allele A3 shows a significant OR
and is rarer than allele A4 it is, from a popula-
tion genetic point, the most likely allele associ-
ated to ROA. We, therefore, have chosen to
further investigate the eVect of allele A3. To
retain suYcient numbers (power) the homo
and heterozygous genotypes with allele A3
were added and used to perform stratified
analysis by sex and by separate joint sites in
ROA+ subjects. The overall adjusted OR
calculated for homo and heterozygous carriers
of the A3 allele together using the remaining
Table 1 Population description ERGO cohort of 55–65 years and allele frequencies of the
dinucleotide repeat polymorphism in the promoter region of the IGF-I gene
Overall ROA+ ROA−
Subjects (n) 786 651 135
Characteristics of subjects
Men (% of total) 317 (40) 254 (39) 63 (47)
Age (y) (SD) 60.5 (2.7)* 59.5 (2.7)
BMI (kg/m2) (SD) 26.6 (3.7)* 25.1 (3.1)
BMD (g/cm2) (SD) 0.87 (0.13) 0.86 (0.12)
Allele frequencies (no of alleles)
Alleles† Weber‡ (88) Overall (1572) ROA+ (1302) ROA− (270) Ë§ p
A2 0.18 0.07 0.07 0.07 4.9 0.02
A3 0.16 0.19 0.20 0.13
A4 0.60 0.66 0.65 0.72
A5 0.06 0.05 0.05 0.05
other 0.00 0.04 0.04 0.04
*Significantly diVerent from the control group with p<0.01. †IGF-I alleles with nomenclature as
in Weber and May.15 ‡Allele frequencies as in Weber and May.15 §Likelihood-ratio test statistic =
−2ln(L(H0)/L(H1)).
Table 2 Odds ratios of subjects with IGF-I genotypes containing allele 3 compared with
all other genotypes
Subjects
No of A3 genotype (frequency)
−/− −/+ OR (95% CI)* +/+ OR (95% CI)*
ROA− 103 (0.76) 30 (0.22) 1 2 (0.01) 1
ROA+ 417 (0.64) 211 (0.32) 1.9 (1.2, 3.1) 23 (0.04) 3.6 (0.8, 16.2)
*Odds ratio adjusted for age, body mass index, bone mineral density.
Table 3 Odds ratios of subjects with IGF-I genotype containing allele 3 (homo and
heterozygote) compared with all other genotypes
Subjects Number
Number of
other genotypes
(frequency)
Number of A3
genotypes
(frequency)
Crude OR (95%
CI)
Adjusted OR
(95% CI)*
Total 786 520 (0.66) 266 (0.34)
ROA− 135 103 (0.76) 32 (0.24) 1 1
ROA+ 651 417 (0.64) 234 (0.36) 1.8 (1.2, 2.8) 2.0 (1.3, 3.1)
Knee ROA 142 96 (0.68) 46 (0.32) 1.5 (0.9, 2.6) 1.8 (1.0, 3.4)
Hip ROA 71 42 (0.59) 29 (0.41) 2.3 (1.2, 4.2) 2.8 (1.4, 5.7)
Hand ROA 444 284 (0.64) 160 (0.36) 1.8 (1.2, 2.9) 2.2 (1.4, 3.5)
Spine ROA 479 308 (0.64) 171 (0.36) 1.8 (1.2, 2.9) 2.0 (1.2, 3.2)
*Odds ratio adjusted for age, body mass index, bone mineral density.
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genotypes as reference was 2.0, 95% CI 1.3,
3.1. This association with IGF-1 A3 genotypes
was found in both men (adjusted OR = 2.4,
95% CI 1.2–4.8) and women (adjusted OR =
1.8, 95% CI 1.0–3.3) being strongest in men.
When subjects were selected on joint site
specific ROA, a significant eVect of the IGF-1
genotype with allele 3 was observed for each
individual joint (table 3). The strongest eVect
as measured by the OR was observed in
subjects with hip ROA with an adjusted OR of
2.8, 95% CI 1.4, 5.7. When subjects were
stratified by number of joint groups aVected
(knee, hip, hand, and spine) the strength of the
association measured by the OR of A3
genotypes was not higher for subjcets with
ROA in > 3 joint sites (generalised ROA).
Discussion
We investigated whether a polymorphic marker
of the IGF-1 gene is associated with the
presence of ROA at knee, hand, hip, and spine.
In a population-based cohort of 786 subjects,
the frequency of the subjects heterozygous for
the IGF-1 allele A3 was found to be approxi-
mately two times increased in ROA+ subjects
compared with ROA− subjects (adjusted OR
1.9, 95% CI 1.2, 3.1). A 3.5 times increased
frequency of the A3/A3 homozygous IGF-1
genotype was observed among subjects with
ROA+ (adjusted OR 3.6, 95% CI 0.8, 16.2).
The latter association was not significant,
probably because of the small number of
subjects homozygous for IGF-1 allele 3 (for
ROA− n= 3, for ROA+ n=23). The associa-
tions observed were not explained by age, sex,
BMD, or BMI.7 10 11 The deviation of IGF-1
allele A4 may be a consequence of compensat-
ing allele frequencies.Moreover, no association
was found between IGF-1 alleles and BMD or
BMI nor did we observe an association of
IGF-1 locus with the presence of osteophytes
in the knee as has been suggested for serum
IGF-1 concentrations6 (results not shown). As
association studies are subject to false positive
results the observed associations requires
cautious interpretation and replication in a
second population-based study.
In view of the function of IGF-1 in articular
cartilage metabolism and the intragenic loca-
tion of the dinucleotide repeat polymorphism,
the association found may be because of the
role of the IGF-1 gene in the onset of ROA.
We, however, cannot exclude the possibility
that a gene closely linked to the IGF-1 locus,
influences the association. Two other genes on
chromosome 12 that may play a part in the
onset of OA are the procollagen type II
(COL2A1)18 and the vitamin D receptor
(VDR) genes.19 The location of these genes,
however, is on 12q12–14, which is at least 80
cM of the IGF-1 gene. As in unrelated subjects
linkage disequilibrium extends only over short
genetic distances (1–2 cM), it is not likely that
mutations in these genes cause the currently
described associations.
In addition to IGF-1, genotypes of a
polymorphism in the gene encoding the recep-
tor of the IGF-1 gene20 were studied but did
not show any association in subjects with ROA
in the knee and/or the hip as compared with
subjects without ROA (results not shown).
Although the IGF-1 polymorphism is lo-
cated in the promoter region, and may aVect
the expression of the gene, its relation to IGF-1
concentrations is not yet known. The associa-
tion observed may be explained by diVerences
in carriers versus non-carriers in the response
of the chondrocyte, via IGF-1, to cartilage
damage and degradation during the OA
process.4 5 The observation that IGF-1 allele 3
is associated with ROA at any joint site (knee,
hip, hand, and spine) and does not increase
specifically for subjects with generalised ROA
may indicate a mild genetic predisposing effect,
which phenotypic outcome may depend on
other factors, for example, mechanical stress.
Carriers of the IGF-1 allele 3 may thus be pre-
disposed to ROA at any possible joint.
The observed association was strongest in
subjects with hip ROA, a site for which the role
of genetic factors was not previously assesed. It
has, however, been reported that ROA of the
hip has a specific sex and geographically preva-
lence pattern, which may suggest the involve-
ment of systemic factors to the onset of hip
ROA. Furthermore, hip ROA is often consid-
ered to arise because of anatomical
abnormalities.21 As IGF-1 is expressed during
developmental stages and plays an important
part in cartilage formation,22 the eVect of the
IGF-1 locus may be exerted via this way.
In our population-based study we were able to
study specifically the pathophysiology of ROA of
the hip, knee, hand, and spine. Our selection
criteria for ROA negative subjects were strict in
that we included only subjects without ROA at
any of the four joints studied. Because of the
high prevalence of hand and spine ROA only
135 (17%) ROA negative subjects fulfilled these
criteria. This may have contributed to the detec-
tion of association because the observed associa-
tion was mainly a result of the reduced
frequency of allele A3 in subjects without ROA,
suggesting that the absence of this allele in par-
ticular in the genotype lowers the risk for ROA.
It is also possible that another IGF-1 allele pro-
tects subjects without ROA. The frequency of
IGF-1 allele 4 in this respect, is higher among
subjects without ROA and may possibly protect.
The relative high allele frequency of this allele,
however, may have decreased power to signifi-
cantly prove such a protective eVect. The
independent eVect of allele A3 and A4 could not
be tested by exclusion of subjects with either
IGF-1 because the remaining number of sub-
jects was not suYcient.
Our study, shows an association of IGF-1
genotype with the prevalence of ROA in knee,
hip, hand, or spine irrespective of BMD, BMI,
and age. These findings suggest that IGF-1
plays a part in OA pathogenesis.
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